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Abstract: The contraceptive vaginal ring is a novel contraceptive method that offers unique 
advantages. Intravaginal delivery of both estrogen and progesterone allows continuous release 
of medication, resulting in lower systemic levels. The use of long-term combined hormonal 
contraception enables improved cycle control compared with progesterone-only methods. The 
indications and usage of the NuvaRing® are described along with the efficacy, tolerability, and 
safety. Overall, the contraceptive vaginal ring appears to be very effective, with a favorable 
side-effect profile, and is highly acceptable to most patients.
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Introduction
An ideal contraceptive would be highly effective, discreet, easy, and painless to use, 
and require no intervention by medical personnel. The method should have   reversible 
effects and cause minimal interference with daily life and bodily functions. The drug 
should have high bioavailability, have low variability in serum levels, and cause minimal 
interference with other medications.1
The vaginal ring meets many of these criteria as the avoidance of first-pass 
metabolism by the liver enables lower dosing with continuous release and sustained 
levels of medication. The highly vascular nature of the vaginal mucosa, coupled 
with low sensitivity to foreign bodies, also contributes to the utility of vaginal 
administration. Single application by the user allows the convenience of long-term 
dosing and thus increased patient compliance. Avoidance of the fluctuations in 
hormone levels resulting from daily pill ingestion decreases side effects and may 
also improve compliance.
While long-acting forms of progesterone-only contraception have long been 
available, the lack of estrogen supplementation often results in increased rates of 
unscheduled bleeding. For many years, combined hormonal contraception including 
both estrogen and progesterone was available only in pill form. This method requires 
daily intake, with a common complaint of nausea as a side effect. In addition, intes-
tinal absorption was unreliable due to multiple causes including interuser variation, 
vomiting, drug – drug interactions, and decreased intestinal absorption. Recently, 
combined hormonal contraception has become available in injection, transdermal 
patch, and now vaginal rings.International Journal of Women’s Health 2010:2
Table 1 Patient considerations with the combined vaginal 
contraceptive ring
Contraindications
History of cardiovascular events
venous thromboembolism
Advanced hypertension or diabetes
Liver disease
Headaches with neurological manifestations
Smokers older than 35 years of age
Women with known or suspected breast, endometrial, vaginal, 
or cervical cancer
Undiagnosed abnormal vaginal bleeding
Additional counseling may be required for women with:
Personal history of benign breast disease
Family history of breast cancer
Diabetes, hyperlipidemia, hypertension
Migraine
Depression
Gallbladder, liver, heart, or kidney disease
Smokers younger than 35 years of age
Close surveillance needed in patients with:
History of vaginal irritation
Uterovaginal prolapse
Severe constipation
History of toxic shock syndrome
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The NuvaRing®
Several vaginal contraception rings have been developed 
worldwide since the 1960s. These include progesterone-
only formulations in various sizes and shapes. Approved by 
the Food and Drug Administration in 2001, the NuvaRing® 
(Organon, Kenilworth, New Jersey) is a nonbiodegradable, 
latex-free, flexible, transparent, colorless, combined con-
traceptive vaginal ring composed of ethylene vinyl acetate 
copolymers and magnesium stearate. The ring contains 
2.7 mg of ethinyl estradiol (EE) and 11.7 mg of etonogestrel. 
After placement in the vagina, each ring releases on average 
0.015 mg/day of EE and 0.120 mg/day of etonogestrel over 
a 3-week period of use.
Indications and contraindications for use
The NuvaRing is indicated for prevention of pregnancy; 
however, additional benefits include improved cycle control 
and reduction in menorrhagia and dysmenorrhea. A report 
on the clinical use of the ring reveals no idealized patient 
for whom it is particularly suited, rather acceptability is high 
among younger and older reproductive-age women regardless 
of parity.2 Absolute contraindication to the NuvaRing relate 
mostly to the presence of estrogen (Table 1) and include 
history of cardiovascular events or venous thromboembolism 
(VTE), advanced hypertension or diabetes, liver disease or 
headaches with neurological manifestations, and smokers 
older than 35 years of age. The ring should not be used in 
women with known or suspected breast, endometrial, vaginal, 
or cervical cancer, or undiagnosed abnormal vaginal bleeding. 
  Additional counseling may be required in women with per-
sonal history of benign breast disease, family history of breast 
cancer, diabetes, hyperlipidemia, hypertension, migraine, 
depression, or gallbladder, liver, heart, or kidney disease, 
and in those who smoke cigarettes. Estrogen-containing 
contraception should not be initiated within 30 days prior to 
a planned surgery, but need not be discontinued.
In addition, close surveillance may be needed in patients 
with history of vaginal irritation, uterovaginal prolapse, 
severe constipation, and history of toxic shock syndrome.
Use of the NuvaRing
The NuvaRing is inserted by the patient herself and is to 
remain in place for 3 weeks, followed by a 1-week ring-free 
period. Subsequently, a new ring is placed and the cycle is 
repeated. The ring is compressed into a more linear shape by 
the user and then placed high in the vagina, where it resumes 
a ring shape. The ring does not need to be precisely positioned 
inside the vagina.
An in vivo study using magnetic resonance imaging was 
conducted to establish the anatomic location of the ring in a 
nulliparous and a multiparous woman.3 The ring was found to 
lie above the urogenital diaphragm, surrounding the cervix, 
and was slightly compressed by the vaginal walls to form 
an ovoid shape. Of note, there was no displacement of the 
urethra with ring use. After ambulation, the ring was noted 
to move cephalad, with a more pronounced change in the 
nullipara (Figure 1).
Withdrawal bleeding is to be expected within 2–3 days of 
removal of the ring and may still continue past the proscribed 
7-day ring-free period. The new ring must be inserted 1 week 
after the removal of the prior ring to maintain contraceptive 
efficacy. Ideally, the NuvaRing should be inserted on cycle 
day 1. If inserted later, a backup method of contraception 
should be used for the first 7 days of ring use. The ring can 
be inserted within 5 days of a first trimester abortion or 
miscarriage, and beyond this point, backup contraception 
is required. The ring may be removed for up to 3 hours 
without loss of efficacy. If the ring has been removed for 
more than this time during the first or second week of use, 
backup contraception is required. If the ring is left out dur-
ing the third week of use, it can be replaced by a new ring 
with backup contraception or left out for the usual 1-week 
period with subsequent replacement. If left in for more than 
4 weeks, the ring should be removed for 7 days or replaced, International Journal of Women’s Health 2010:2
Figure 1 The contraceptive vaginal ring is positioned high in the vagina.
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with backup contraception use required until 7 days after the 
next ring was placed.
As was common with combined oral contraception (COC), 
deviations from standard use including continuous use of the 
NuvaRing for suppression of menses are often suggested by 
gynecologists to decrease menorrhagia, to decrease dysmenor-
rhea, or for patient convenience. Common sense would advise 
similar caveats as for COCs regarding balancing the length of 
menstrual suppression with increasing risk of irregular bleed-
ing as use is extended. Shortening the ring-free interval may be 
appropriate for certain patients as will be discussed below.
Efficacy
Pregnancy rates
Pregnancy rates with the vaginal ring appear to be low. In 
phase 3 trials, the Pearl index was 0.65 pregnancies per 
100 woman-years of use; however, 50% of the six pregnan-
cies occurred in protocol violators.4 In a large, international, 
multicenter observational trial, the Pearl index was 1.18.5 In 
other studies, comparing the vaginal ring with COC, results 
ranged from no pregnancies in either group6 to a Pearl 
index of 0.25 compared with 0.99 with COC, among those 
in the intention-to-treat groups.7 Cited pregnancy rates for 
1-year use of COC, NuvaRing, and the transdermal patch 
are all set at 8% for typical use and 0.3% for perfect use. 
Given low rates of pregnancy on COC, it is likely that the 
studies needed to prove superior efficacy of methods with 
the promise of greater compliance over COC would not be 
feasible.8
Mechanism of action
As with COC, the chief mechanism of action is the inhibi-
tion of gonadotropins and prevention of ovulation along 
with effects on cervical mucus and endometrial histology. 
Clinical studies show that the maximum serum concentra-
tion of EE is attained after 2–3 days, whereas the maximum 
level of etonogestrel is attained after 1 week. Serum levels 
then decrease progressively and linearly.9 Total exposure to 
estrogen (area under the curve) was 3.4 times higher than 
that for the NuvaRing and 1.6 times higher than that for a 
30 µg EE COC.
While serum levels are low, the contribution of the “uterine 
first pass” effect is unknown. When uterine levels were studied 
in hysterectomy specimens in women pretreated with either 
a 20 µg EE COC or the NuvaRing, uterine hormone levels 
were comparable in the upper and mid myometrium, and the 
cervical region. Conversely, endometrial concentrations of 
estrogen were higher in the COC group. These results favor 
continuous dosing with the vaginal ring as the driving force 
behind improved cycle control compared with users of low-
dose COC.10
Prevention of ovulation
Complete inhibition of ovulation as measured by follicle 
formulation and luteinizing hormone (LH) and progester-
one levels was found during the typical 3 weeks of use and 
for 2 additional weeks.11 The endometrium was found to be 
thinned in all subjects and was comparable to the COC group. 
Serum follicle-stimulating hormone and 17β-estradiol levels International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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were highest during the first week of use, reflecting innate 
hormonal activity prior to insertion.
The same investigators tested ovulation suppression under 
conditions of atypical use as well, with notable findings.12 
Following a typical-use cycle, insertion for as few as 3 days 
will delay ovulation. In addition, delay of reinsertion until 
follicles reached 13 mm will still inhibit ovulation, even with 
these larger follicles. In this group, 50% of women required 
more than 4 days until follicles reached this threshold and 
none subsequently ovulated. Despite the development of 
follicles when reinsertion is delayed, the LH surge is likely 
still inhibited once the ring is inserted. Subsequent follow-up 
in the next untreated cycle revealed that ovulation occurred 
in 27 of 29 women, highlighting the rapid return to fertility 
after discontinuation of this method.
In women with documented ovulation on cycle days 
9–12, follicle growth was not suppressed by the NuvaRing 
compared with a 30 µg EE COC.13 If escape ovulation occurs 
in these women, pregnancy may still be prevented due to 
effects on cervical mucus and endometrial histology. If ovula-
tion does not occur, these larger follicles may develop into 
cysts. These investigators, thus, recommended reducing the 
treatment-free interval to 5 days or skipping it completely in 
women with ovulation prior to cycle day 12 or if the entire 
cycle length is less than 26 days.
Factors that might modify efficacy
Multiple factors that might be presumed to affect the efficacy 
of the NuvaRing have been studied, with overall minimal 
interactions. The use of a nonoxynyol-9-containing sper-
micide14 or tampon co-usage15 was not found to affect hor-
mone levels, efficacy, or tolerability. The use of antimycotic 
medications was found to increase systemic hormone levels, 
with lower drug levels present in the ring when assayed after 
removal. This effect was more pronounced when multiple 
doses of suppositories were used compared with comparable 
doses of cream; however, these changes were not expected 
to influence efficacy or tolerability.16 No change in serum 
concentration of hormones was noted during the usage of 
oral amoxicillin or doxycycline.17 Of note, unlike COCs 
and the transdermal patch, body weight does not appear to 
influence efficacy.18
Cycle control
Predictable patterns of bleeding while on hormonal con-
traception are highly desirable to patients, with consistent 
monthly scheduled bleeding and low rates of unscheduled 
bleeding. One of the unique aspects of the ring is the excellent 
cycle control afforded despite overall low serum levels of 
estrogen. The ring releases 15 µg of EE daily, and   comparable 
low-dose COCs are well known to result in patterns of 
breakthrough bleeding. In phase 3 trials, cycle control was 
found to be excellent, with irregular bleeding noted in only 
2.6%–6.4% of cycles.4
In trials comparing the NuvaRing with various 30 µg EE 
COCs, the ring was noted to have lower incidence of break-
through bleeding even in the first cycle.19,20 In addition, there 
was an increased rate of scheduled bleeding and a decreased 
rate of late-withdrawal bleeding.
Withdrawal bleeding provides monthly reassurance 
to patients regarding absence of pregnancy. In the phase 
2 trial, withdrawal bleeding was only absent in 0.6%–2.1% 
of cycles.4 Early-withdrawal bleeding, occurring prior to 
ring removal, was present in 5.4%–7.7% of cycles. Late-
withdrawal bleeding that persisted past the 7-day ring-free 
period was noted in 20.4%–27.3% of cycles, but consisted 
mostly of spotting. As one in five women may experience 
this spotting, the importance of prompt reinsertion must be 
emphasized, given the possibility of escape ovulation if ring 
reinsertion is delayed.
extended use
Continuous or extended use of combined hormonal con-
traception is often advised by gynecologists to decrease 
menorrhagia, dysmenorrhea, menstrual migraines, and 
premenstrual symptoms. Extended use with replacement 
of the ring every 21 days for 84 continuous days of use for 
1 year resulted in increased rates of irregular bleeding dur-
ing the first 4-month interval. Subsequently, there was small 
decrease in the number of scheduled bleeding days, with 
bleeding occurring on 15 of the 28 possible bleeding days.21 
Only 4% of women who discontinued the vaginal ring cited 
this pattern of bleeding as the cause. A similar trial evaluated 
28-, 49-, 91-, and 364-day cycles and noted that the median 
number of scheduled bleeding days increased with longer 
cycle duration. There was an accompanying increase in the 
days of unscheduled bleeding, which was mostly spotting.22 
Contraceptive efficacy remained similar with reduced dys-
menorrhea, menstrual migraine, and premenstrual symptoms 
with extended use. Patients reported higher satisfaction with 
shorter cycles; however, the trial did not evaluate satisfaction, 
especially in women with menorrhagia, who might tolerate 
a greater degree of spotting. Management of unscheduled 
bleeding while on an extended regimen was evaluated in 
women replacing the ring every 4 weeks for 6 months.23 Those 
women randomized to remove the ring for 4 days following International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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5 days of continuous bleeding were noted to subsequently 
have absence of spotting on an increased number of days 
compared with those who kept the ring in place.
Tolerability
The side effects attributed to contraceptive use are varied 
and play a crucial role in determining continuation rates. 
Commonly reported side effects related to NuvaRing use are 
headache, vaginitis, weight gain, and nausea.24
Headaches were reported in 3.3% of ring users com-
pared with 2.4% of those using a 30 µg EE COC in a trial of 
264 women.19 In noncomparative studies, headaches were 
reported by 5.5%–5.8% of ring users.5,24
Compared with COC users, ring users report increased 
rates of vulvovaginal complaints, such as discharge, vaginal 
irritation, vaginitis, and leukorrhea,25,26 and more women 
cited these concerns as the reason for discontinuation 
compared with COC users.5,26 In one of the observational 
studies, vaginitis symptoms were reported by 13.7% of 
women subjects.5
Most cases of vaginitis were due to candidal infection,26 
and the most common strains all show high adherence to the 
ring. The in-vitro adherence of different yeasts was studied 
using isolates from vaginal exudates of patients with vul-
vovaginal candidiasis. Candida albicans adhered the least, 
followed by, adherence in increasing order, C. parapsilosis, 
Saccharomyces cerevisiae, C. tropicalis, and C. glabrata.27 
Thus, the presence of recurrent yeast infection in women 
using vaginal rings may be characterized by infection with 
less common species.
Foreign body effects on the vaginal surface have not been 
evaluated with the NuvaRing but were studied in four other 
contraceptive vaginal rings: Nestorone® (Watson Pharmaceu-
ticals, Inc- Corona, CA, USA) EE/Nestorone, EE/norethin-
drone acetate (over 4 months), and EE/norethindrone acetate 
(over 12 months). A total of 17.4% of inspections showed 
atypical conditions of the vaginal surface appearance, many 
being subtle. These findings included all ulcerations, abra-
sions, and ecchymoses. The majority of atypical conditions 
(83%) disappeared by the next scheduled colposcopy despite 
continued ring use, indicating that the vaginal rings contribute 
little to clinically significant lesions.28
Varying results have been reported on the effect of 
the NuvaRing on body weight. Three studies comparing 
the NuvaRing and the oral contraceptives showed weight 
neutrality with the NuvaRing use.19,20,26 In one study, 
a clinically significant decrease in body weight was noted 
in the   NuvaRing group compared with the COC group.26 
In another study, a clinically significant increase in body 
weight was noted in the COC group compared with the 
NuvaRing group, with an overall small mean change in 
body weight in both groups.19 In an observational study, 
body weight and body mass index remained stable on the 
NuvaRing group, with 86.9% of subjects experiencing 
no relevant change.25 In contrast, 6.1% of the ring users 
in an observational study reported a significant weight 
increase from baseline although perception of weight 
change was minimal. It is possible that modified eating 
behaviors due to fear of weight gain may have played a 
role in the results.
While nausea is one of the more frequently reported side 
effect of the NuvaRing use, the actual incidence appears 
to be lower compared with low-dose COC use, probably 
related to the avoidance of the gastrointestinal tract. In an 
observational study, nausea and gastrointestinal side effects 
were reported in 2.5% of subjects. This is also reflected by 
data from the comparative trials, with rates of 2.7% in ring 
users compared to 4% of those taking 30 mg EE/150 mg 
levonorgestrel (LNG).19,24
Nausea has also been reported with a vaginal ring 
releasing 20 µg EE/1 mg norethindrone acetate. The 
effects on nausea with different insertion regimens of this 
ring were studied. Transient nausea was seen following 
insertion of a new ring, lasting from 0.5 to 48 hours. The 
study concluded that the incidence of nausea was highest 
with bedtime insertion. Transient vomiting occurred in 
approximately 10% of women in the first 24 hours after 
first insertion of a new ring. Nausea decreased with early 
evening insertion, temporary removal during the first 
night, and overnight soaking of the ring in water before 
use. Incidence of nausea also decreased during the second 
cycle of each regimen.29
Safety
The use of the vaginal ring was not found to significantly 
affect blood pressure. No clinically relevant change from 
baseline was seen during observational trials or postmarketing 
surveillance in either diastolic or systolic blood pressure.5,25 In 
a trial comparing COC and NuvaRing use, #4% of subjects 
in each treatment group experienced hypertension.26
No significant changes in cervical cytology have been 
attributed to NuvaRing use. In an observational trial, a 
total of 1.3% of subjects changed from normal cytology 
to low-grade squamous intraepithelial lesions and 0.4% of 
subjects changed to high-grade squamous intraepithelial 
lesion/carcinoma in situ. Normal shifts in cervical cytology International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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may have been detected because of the frequent screening 
during the study.5
Development of VTE is of great concern with the use of 
combined hormonal contraceptive. While the absolute risk 
of VTE with the use of the contraceptive vaginal ring has not 
been established, cases have been reported during clinical 
trials. In comparative studies, single reports of deep vein 
thrombosis were seen, thought to be possibly related to the 
NuvaRing.19,26 One report of cerebral venous sinus thrombo-
sis was seen with NuvaRing use.30 A case report by Voora and 
Vijayan31 identified development of a mesenteric vein throm-
bosis associated with intravaginal hormonal contraceptive 
use, 3 months after initiation in a 32-year-old nonsmoking 
female, with no risk factors or hypercoagulability.31
Both the NuvaRing and oral LNG/EE are associated 
with a minimal effect on hemostatic variables. Factor VII 
levels increased in the NuvaRing group and decreased in the 
LNG/EE group. Antithrombin activity and protein C activ-
ity were reported to be higher in the NuvaRing group. The 
anticoagulation and fibrinolytic activities were comparable 
between the NuvaRing and oral LNG/EE groups. Levels of 
tissue plasminogen activator decreased in both groups, but 
the reduction was smaller in the NuvaRing group. There 
were no significant differences in fibrin turnover between 
the treatment groups.32
The NuvaRing may represent an appropriate choice for 
contraception use in women at risk for developing diabetes 
mellitus or metabolic syndrome.33 It has been shown to be a 
safe form of contraception in late-reproductive-age women 
with type 1 diabetes mellitus, as no clinically significant 
effect on carbohydrate metabolism was seen, compared with 
the control group of age-matched women with type 1 diabe-
tes mellitus using no contraception.34 Also in a comparative 
study, insulin sensitivity significantly decreased during COC 
use and tended to increase during vaginal administration of 
hormonal contraceptives.33
Other comparative studies show similar results, report-
ing a lesser impact on carbohydrate metabolism compared 
with low-dose combined oral contraceptive use. A greater 
reduction in free androgen and dehydroepiandrosterone 
sulfate levels was seen with the ring use compared with pill 
treatment. The basal insulin resistance was slightly decreased, 
but a significant reduction in the insulin sensitivity index was 
found in women on pill therapy compared with those in the 
ring group (P , 0.035). Pancreatic β-cell function was not 
significantly altered with either treatment.35
In the study by Duijkers et al,36 no clinically rel-
evant effects were seen on adrenal or thyroid function 
(free thyroxine) with both the NuvaRing and the oral con-
traceptive use. There was a significantly lower increase in 
concentrations of cortisol-binding globulin and total cortisol 
during the ring use compared with COC. In the comparative 
study by Cagnacci et al,33 γ-glutamine transferase slightly 
increased in the oral group and slightly decreased in the 
vaginal group (P = 0.04).
The NuvaRing has been shown to have minimal effect on 
lipid profile, with no change seen in total cholesterol, high-
density lipoprotein (HDL) cholesterol, and low-density lipid 
cholesterol in observational trials. When the ring was com-
pared with a combined oral contraceptive (30 µg EE/150 µg 
LNG), stable total cholesterol was found in both groups, 
along with increases in apolipoprotein B and triglycerides. 
In contrast to a decrease in HDL, HDL2, and HDL3 levels 
in the COC group, HDL2 increased in   NuvaRing group. 
Apolipoprotein A-1 levels increased in NuvaRing group but 
decreased in COC group, and lipoprotein(a) decreased in 
both groups. Sex-hormone-binding globulin increased mark-
edly more with NuvaRing, whereas corticosteroid-binding 
globulin levels increased to a lesser degree. These changes 
may reflect the lower androgenicity of etonogestrel compared 
with levonorgestrel.37
The effect of the contraceptive vaginal ring on bone 
mineral density (BMD) was studied in an open-label mul-
ticenter cohort of premenopausal women and nonhormonal 
contraceptive users. There were no changes from baseline 
z scores in the contraceptive ring group in both the spine 
and the femoral necks. The control group BMD showed 
an increase from baseline, resulting in a significant differ-
ence (P , 0.0001) between the two groups at 24 months. 
Therefore, there was a decreased acquisition of peak bone 
mass in the contraceptive ring group. The study concluded 
that the use of contraceptive ring for 2 years did not produce 
changes in BMD in healthy premenopausal women, as the 
differences were within 1 standard deviation of one another. 
There was no assessment of fracture risk, an outcome with 
greater clinical relevance.38,39
There is approximately 85% of remaining EE load 
after the NuvaRing’s use. An assessment was performed 
on the potential environmental exposure in landfills from 
discarding the hormonal ring in household waste. This 
study concluded that EE does not have a high mobility 
in landfills and soils. Column experiments estimate the 
duration of 40 years before EE leaches from a column 
of 1 m of landfill material. This makes emission from 
landfills negligible and reduces   potential for groundwater 
contamination.40International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Ease of use is one of the features of the NuvaRing that 
increase acceptability. Women can generally be reassured that 
as long as the vaginal ring stays in place, it has been positioned 
correct. The solitary exception is intravesicular placement. 
Currently, there are two case reports of accidental self-insertion 
of the NuvaRing into the bladder with subsequent symptoms 
of urinary urgency, frequency, and pelvic pain until the ring 
was located and removed.41,42 Insertion instructions should, 
thus, be reviewed with the patient and insertion demonstrated 
in the office if necessary. Any unusual or persistent complaints 
in users of vaginal rings should be carefully investigated.
Patient acceptability
Patient acceptability of any contraceptive method involves 
multiple factors, including ease of use, side-effect profile, 
and efficacy. As in all clinical interventions, realistic expecta-
tions and careful patient counseling are vital components in 
improving compliance. An additional hurdle with the use of 
a contraceptive vaginal ring is acceptance of the new route 
of administration.
Compliance and ease of use
In phase 3 trials, compliance was reported in 90.8% of cycles, 
with a prolonged ring-free interval in 4.1% of women.42 
During the trial, 29.6% of women discontinued the ring, 
most during the first 3–4 cycles. Reasons cited were device 
related, including foreign body sensation, discomfort with 
coitus, and ring expulsion rather than irregular bleeding. 
Insertion and removal were felt to be simple. Overall, 96% 
of women stated they liked the ring and 98% would recom-
mend it to others.
In an international multicenter trial, the rate of ring 
removal was 1.2% in the United States compared with 0.28% 
in Europe.5 Of note, the contraceptive failure rate was also 
higher in the United States compared with Europe.
In a large trial of women randomized to the NuvaRing 
or 30 mg EE/150 µg of LNG, the ring-free period was pro-
longed in 6.6% of cycles compared with 2.9% cycles with a 
prolonged pill-free period.26
Satisfaction rates
In a large administrative claims database, the transdermal 
patch and transvaginal ring were 1.6 and 1.7 times more likely 
to be discontinued at 3 months than COC.43 This study does 
not detail whether desire for pregnancy, adverse events, or 
cost factors contributed to discontinuation.
In contrast, telephone callback rates were the lowest with 
the ring compared with the transdermal patch and COC in a 
population of previous COC users, and most complaints were 
related to ring expulsion or partner complaints.44
User acceptability was studied in the United States, 
Canada, Germany, Austria, Norway, Sweden, Denmark, 
Finland, France, the Netherlands, Belgium, Spain, the 
United Kingdom, and Israel.45 At entry, the COC was cited 
as the contraceptive of choice; however, after 3 cycles, 81% 
preferred the ring. The most commonly reported reason for 
dislike was that the ring was falling out. In past users of 
COC randomized to the NuvaRing or the transdermal patch, 
70.6% desired to continue the NuvaRing and 21.6% desired 
to resume COC use.6
Sexual activity
Evidence for a change in libido with the use of COC is equiv-
ocal. Vaginal delivery of contraception, therefore, requires 
scrutiny regarding effects on sexual activity. In women 
randomized to NuvaRing or a COC containing desogestrel 
and 30 µg EE, improvement in sexual function across several 
spheres was noted in both groups.46 The NuvaRing group had 
increased rates of sexual fantasy and sexual frequency, and 
their partners reported increase in sexual interest, complicity, 
and sexual fantasy. While a placebo group using an inert 
ring was not included, the authors speculate that the presence 
of a foreign body may be stimulating to both partners and 
in addition serve as a reminder of contraceptive efficacy, 
further decreasing anxiety during intercourse.
Conclusion
The contraceptive vaginal ring, thus, represents an efficacious 
and well-tolerated means of hormonal contraception. Long-
term, continuous release via vaginal administration confers 
unique benefits with this method. The ring has a favorable 
adverse event and side-effect profile. Individualized patient 
assessment to identify appropriate users and careful counsel-
ing to ensure correct use and create realistic expectations can 
improve compliance rates with this novel contraceptive.
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